<DOC>
	<DOCNO>NCT01617681</DOCNO>
	<brief_summary>To assess efficacy , safety tolerability valsartan compare two dos valsartan reduce control blood pressure child hypertension without CKD .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Multiple Doses Valsartan Children With Hypertension With Without CKD</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients eligible inclusion study fulfill follow criterion : Have ability provide write informed consent ; Have baseline , document diagnosis hypertension ( define National High Blood Pressure Education Program 2004 ) ; MSBP ( mean 3 measurement ) must ≥95th percentile , ≤25 % 95th percentile , age , gender height , baseline ; CKD patient must define follow criterion : Kidney damage ≥3 month , define structural functional abnormality kidney , without decrease GFR , manifest one follow feature : Abnormalities composition urine , Abnormalities image test , Abnormalities kidney biopsy , Estimated eGFR &lt; 60 mL/min/1.73m2 ≥3 month , without sign kidney damage describe ; Able swallow valsartan solution ; Body weight must ≥8 kg ≤40 kg baseline ; Must able safely washout antihypertensive therapy ( applicable ) Exclusion criterion AST/SGOT ALT/SGPT &gt; 3 time upper limit reference range ; Estimated Glomerular Filtration Rate [ eGFR ] &lt; 30 mL/min/1.73m² ( calculate use Modified Schwartz Formula ) ; Serum potassium &gt; 5.3 mmol/L ; Uncontrolled diabetes mellitus , define investigator ; Unilateral , bilateral graft renal artery stenosis ; Current diagnosis heart failure ( NYHA Class IIIV ) ; Patients take follow concomitant medication follow screening : RAAS blocker study drug , Lithium , Potassiumsparing diuretic , potassium supplement , salt substitute contain potassium substance may increase potassium level ; Nonsteroidal antiinflammatory drug ( NSAIDS ) , include selective COX2 inhibitor , acetylsalicylic acid &gt; 3g/day , nonselective NSAIDs ( paracetamol/acetaminophen permit ) ; Antidepressant drug class MAO inhibitor ( e.g . phenelzine ) ; Chronic use stimulant therapy ADD/ADHD ; patient coarctation aorta gradient ≥30 mmHg ; Previous solid organ transplantation except renal transplantation . Renal transplant must occur least 1 year prior enrollment ; Patient must stable dos immunosuppressive therapy deem clinically stable investigator ; Patients know positive human immunodeficiency virus ( HIV ) Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension ; CKD ; Pediatric</keyword>
</DOC>